BMO Capital Upgrades Halozyme Therapeutics (HALO) to Outperform

Article Stock Quotes (1) Comments (0)

BMO Capital upgraded Halozyme Therapeutics (NASDAQ: HALO) from Market Perform to Outperform with a price target of $12.00 (from $4.00).

For an analyst ratings summary and ratings history on Halozyme Therapeutics click here. For more ratings news on Halozyme Therapeutics click here.

Shares of Halozyme Therapeutics closed at $7.21 yesterday, with a 52 week range of $3.86-$13.50.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• UPDATE: A.G. Lafley Gives Procter & Gamble (PG) Investors 'New Hope', UBS Upgrades to Buy
• Oracle Investment Research Upgrades Procter & Gamble (PG) to Hold
• Baird Upgrades Sherwin-Williams (SHW) to Outperform

Create E-mail Alert Related Categories

Hot Upgrades, Upgrades

Related Entities

BMO Capital

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?